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ABSTRACT
We compared maternal and neonatal outcomes in diabetic pregnancies treated
with either insulin glargine or neutral protamine Hagedorn (NPH) insulin. We performed
a retrospective chart review of diabetic pregnant patients using the Diabetes Care Center of
Wake Forest University during the years 2000 to 2005. Outcomes of interest included
maternal hemoglobin A1C, average fasting and 2-hour postprandial blood sugars, mode of
delivery, birth weight, 5-minute Apgar score < 7, umbilical artery pH < 7.20, incidence of
neonatal hypoglycemia, and pregnancy complications. A total of 52 diabetic pregnant
patients were included in this study. Twenty-seven women used insulin glargine. A total of
13 women used insulin glargine during the first trimester. Glycemic control was similar in
women who used NPH insulin and insulin glargine, as determined by hemoglobin A1C
levels and mean blood sugar values. There were no differences in mode of delivery, average
birth weight, or neonatal outcomes. Maternal and fetal/neonatal outcomes appear similar
in pregnant diabetic women who use either NPH insulin or insulin glargine in combination
with a short-acting insulin analogue to achieve adequate glycemic control during preg-
nancy. Insulin glargine appears to be an effective insulin analogue for use in women whose
pregnancies are complicated by diabetes.
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The incidence of diabetes in the United States
has steadily risen over the past several decades. As a
result, diabetes is one of the most commonly encoun-
tered medical complications of pregnancy. It is well
known that uncontrolled diabetes in pregnancy can
lead to serious fetal, neonatal, and maternal sequelae.
Fetal complications can include congenital malforma-
tions, intrauterine growth restriction, macrosomia,
and intrauterine death. Neonatal complications include
hypoglycemia, hyperbilirubinemia, and respiratory dis-
tress syndrome. Diabetes during pregnancy has also been
shown to increase the risk of development of obesity,
diabetes, and metabolic syndrome in offspring.1,2
Maternal complications associated with diabetes in preg-
nancy include pregnancy-induced hypertension, pre-
eclampsia, and worsening of chronic complications
of diabetes including nephropathy and retinopathy.
Therefore, stringent glycemic control during pregnancy
1Department of Obstetrics and Gynecology, Section on Maternal Fetal
Medicine; 2Diabetes Care Center of Wake Forest University Medical
Center Boulevard, Wake Forest University School of Medicine,
Winston Salem, North Carolina.
Address for correspondence and reprint requests: Jennifer G.
Smith, M.D., Ph.D., Department of Obstetrics and Gynecology,
Section on Maternal Fetal Medicine, Wake Forest University School
of Medicine (e-mail: jgsmith@wfubmc.edu).
Am J Perinatol 2009;26:57–62. Copyright # 2009 by Medical
Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.
Accepted: July 4, 2008. Published online: October 31, 2008.
DOI 10.1055/s-0028-1095181. ISSN 0735-1631.
57
is imperative to ensure a good maternal and fetal out-
come.
Recommendations for glycemic control during
pregnancy are much stricter than in nonpregnant dia-
betic patients: goals are less than 90 to 105 mg/dL
fasting and less than 120 mg/dL 2 hours postprandial.
A goal of less than 140 mg/dL should be used if assessing
blood glucose levels 1 hour postprandial. Various insulin
regimens and formulations have been used in an attempt
to achieve tight glycemic control during pregnancy, none
of which has been shown to be superior.
Insulin glargine is an insulin analogue approved
for clinical use in the United States in the year 2000. Due
to its chemical structure, insulin glargine is very slowly
absorbed, exhibiting a peakless activity profile over a
24-hour time period. Among its attributes, insulin
glargine has been shown to reduce the risk of nocturnal
hypoglycemia in nonpregnant type I and type II diabetic
patients.3–5 Given the strict glycemic control that is
recommended during pregnancy, nighttime hypoglyce-
mia can be a difficult problem to address in pregnant
patients, making insulin glargine an attractive choice for
glycemic management in pregnancy.
Reports of insulin glargine use in pregnancy are
limited.6–14 No adverse effects in human pregnancy have
been reported and animal studies have demonstrated the
safety of insulin glargine during embryogenesis in animal
models.15 This retrospective study provides additional
information regarding maternal and fetal/neonatal out-
comes in pregnancies in which mothers used either
insulin glargine or neutral protamine Hagedorn (NPH)
insulin in combination with other short-acting insulin
analogues for blood glucose management during their
pregnancies.
MATERIALS AND METHODS
After obtaining Institutional Review Board approval, we
conducted a retrospective chart review of pregnant
women and their infants who were treated at the
Diabetes Care Center of Wake Forest University Baptist
Medical Center and delivered at Forsyth Memorial
Hospital. Women treated with either insulin glargine
or NPH insulin during the years 2000 to 2005 were
included. There were no exclusion criteria.
Maternal outcome variables included average
blood glucose values, hemoglobin A1C, and mode of
delivery. Fetal and neonatal outcomes included birth
weight, Apgar score at 5 minutes, umbilical artery blood
gas at delivery, blood glucose at delivery, nadir blood
glucose level, and need for neonatal intensive care unit
(NICU) observation for greater than 4 hours due to
hypoglycemia.
Data were analyzed using t test, one-way analysis




A total of eight type 1, 26 type II, and eighteen gesta-
tional diabetic patients were included in this study. The
demographic data and insulin regimens used by these
women are presented in Table 1. Type I diabetic patients
were significantly younger and had a significantly longer
duration of disease than either type II or gestational
diabetic women.
Of the women using insulin glargine, two women
were using prior to conception and continued its use
throughout their entire pregnancy. Eleven women ini-
tiated use of insulin glargine during the first trimester,
and seven women began using insulin glargine during
the second trimester. The average doses of insulin
glargine at delivery were 59 13.7 IU/d in type I
diabetic women, 65 8.2 IU/d in type II diabetic
women, and 39.7 7.7 IU/d in gestational diabetic
women.
Although hemoglobin A1C data was limited
(first trimester n¼ 17; second trimester n¼ 10; third
trimester n¼ 10), glycemic control was similar between
the NPH and insulin glargine–treated women (Fig. 1).
There were no significant differences in hemoglobin
A1C levels between treatment groups in any trimester
(first trimester p¼ 0.88, second trimester p¼ 0.38,
third trimester p¼ 0.12). Additionally, there was no














Age (ySEM) 24.4 1.5 311.3 35.0 1.3 22 33.31.1 33 1.8
Years diabetic (meanSEM) 12.9 1.9 4.5 1.4 N/A 11 5.11.1 N/A
Nulliparous (%) 57 38 14 100 43 27
Gestational age of initiation of
intermediate or long-acting
insulin (wkSEM)
11.6 3.2 12.31.2 29.9 1.4 1.0 7.0 2.0 30.01.1
NPH, neutral protamine Hagedorn; SEM, standard error of the mean.
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significant difference between hemoglobin A1C levels
within treatment groups over the course of gestation
(insulin glargine p¼ 0.31, NPH insulin p¼ 0.20).
Adequate blood sugar data were available for
analysis for 21 patients who used insulin glargine and
17 patients who used NPH insulin. Fasting blood
glucose levels were significantly lower than postprandial
blood glucose levels in both treatment groups. There was
no significant difference between fasting or postprandial
blood glucose levels in women who used either insulin
glargine or NPH insulin (Fig. 2).
The average gestational age at delivery was
37.0 0.7 weeks gestation in women treated with
NPH insulin and 36.3 0.96 weeks gestation in women
treated with insulin glargine (p¼ 0.56). Of women using
insulin glargine, 37% delivered vaginally compared with
48% using NPH insulin (Table 2). Nine women (33.3%)
using insulin glargine and seven women (28%) using
NPH insulin were delivered by primary cesarean section.
Indications for primary cesarean section included macro-
somia (n¼ 1), failure to progress (n¼ 6), non-reassuring
fetal heart tones (n¼ 3), failed induction (n¼ 1), failed
forceps (n¼ 1), and breech presentation (n¼ 3). There
was no significant difference regarding mode of delivery
between the women who used NPH insulin versus
insulin glargine (p¼ 0.6).
Pregnancy complications in the women using
insulin glargine included preeclampsia (n¼ 2), preterm
premature rupture of membranes (PPROM; n¼ 1), and
intrauterine fetal demise (n¼ 1). The intrauterine fetal
demise occurred at 204/7 weeks gestation in a patient
with a history of venous sinus thrombosis who was being
treated with heparin and baby aspirin. Pregnancy com-
plications in the women using NPH insulin were similar
and included preeclampsia (n¼ 5) and PPROM (n¼ 2).
Neonatal Outcomes
Average birth weights were not significantly different
between patients treated with insulin glargine and those
treated with NPH insulin (3294 189 g and 3274
137 g, respectively; p¼ 0.93). Additionally, there were no
significant differences in the distribution of birth weights
between the NPH insulin and insulin glargine groups
(Table 3). There was only one 5-minute Apgar score< 7.
Although data were limited (insulin glargine n¼ 10,
Figure 1 Hemoglobin A1C values by trimester in women who used insulin glargine and neutral protamine Hagedorn (NPH)
insulin. Data are expressed as mean standard error of the mean.
Figure 2 Fasting and postprandial blood glucose values in women who used insulin glargine and neutral protamine Hagedorn
(NPH) insulin. Data are expressed as mean standard error of the mean. *p< 0.05 compared with postprandial blood glucose
levels.
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NPH insulin n¼ 2), there was no significant difference
between umbilical artery cord gas values (p¼ 0.55).
Neonatal blood sugars on admission to the NICU
were 66.3 3.2 mg/dL in infants of women treated with
NPH insulin (n¼ 20) and 58.9 3.8 mg/dL in infants of
women treated with insulin glargine (n¼ 23; p¼ 0.16).
Nadir neonatal blood sugars were not significantly differ-
ent between groups (50.3 2.8 mg/dL insulin glargine
versus 51.4 2.9 mg/dL NPH insulin, p¼ 0.79; see
Table 3). Thirteen neonates were observed in the
NICU for more than 4 hours after delivery, six from
the NPH-treated group and seven from the glargine-
treated group. Of these infants, three were observed for
only 5 hours. None of the remaining infants were
observed for blood glucose management alone.
Maternal and neonatal outcomes were also deter-
mined for the subgroup of patients for whom adequate
blood sugar data were available, and there were no
significant differences from the data presented above.
DISCUSSION
A pregnancy category class C drug, insulin glargine is an
insulin analogue that was approved for clinical use in
2000. Compared with NPH insulin, insulin glargine use
in nonpregnant diabetic patients is associated with lower
fasting plasma glucose levels, lower hemoglobin A1C
levels, and greater patient satisfaction.5,16 Although
insulin glargine appears superior to NPH insulin in
nonpregnant patients, use of this insulin analogue during
pregnancy has been limited.6–14 These reports have
suggested that insulin glargine use during pregnancy
is effective in achieving adequate glycemic control.
Although randomized, controlled trials have not been
completed, there have been no adverse pregnancy out-
comes reported to suggest than insulin glargine use
during pregnancy is not safe.
This retrospective review comparing maternal and
neonatal outcomes in pregnant women who used either
insulin glargine or NPH insulin as the long-acting
insulin analogue in their insulin regimen adds additional
information to the growing literature regarding insulin
glargine use in pregnancy. Although limited in numbers,
prior animal and human studies have failed to demon-
strate any adverse effects of insulin glargine use during
the first trimester of pregnancy.6,8–10,15 In this retro-
spective review, we report maternal and neonatal out-
comes of an additional 13 women who were exposed to
insulin glargine during the first trimester of pregnancy.
Our study lacks sufficient power to definitively report
that insulin glargine does not cause any adverse outcomes
when used during pregnancy. However, we did not
demonstrate any significant differences in either mater-
nal or fetal/neonatal outcomes between women who
were exposed to either insulin glargine or NPH insulin
during their pregnancy. There were no congenital
anomalies observed in the women who were exposed to
insulin glargine during the first trimester.
Interestingly, almost half of the gestational dia-
betics described in this study were able to use a single
daily injection of insulin glargine alone to control their
diabetes. Therefore, a once-daily dosing regimen using
insulin glargine may be appropriate for a large percent-
age of patients with gestational diabetes. This simplified
insulin administration regimen may improve patient
compliance and therefore decrease the incidence of
complications associated with uncontrolled or poorly
Table 3 Neonatal Outcomes
NPH (n¼25) Insulin glargine (n¼27)
Gestational age at delivery (wkSEM) 37.0 0.7 36.31.0
Birth weight (g)
< 2500 4 2
2500–4000 18 16
4000–4500 3 5
> 4500 0 1
5-min Apgar score < 7 0 1
Uterine artery pH < 7.20 3 (n¼10) 0 (n¼ 3)
Infants staying in NICU for > 4 h (n) 6 7
Neonatal blood sugar on admission (mg/dL) 66.3 3.2 58.93.8
Nadir neonatal blood sugar (mg/dL) 51.4 2.9 50.32.8
NPH, neutral protamine Hagedorn; SEM, standard error of the mean; NICU, neonatal intensive care unit.









Cesarean delivery 13 (52%) 17 (62.9%)
Primary 7 9
Repeat 6 8
NPH, neutral protamine Hagedorn; SVD, spontaneous vaginal delivery;
FAVD, forceps assisted delivery; VBAC, vaginal birth after cesarean.
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controlled gestational diabetes during the third trimester
of pregnancy.
Based on existing literature, two major concerns
exist regarding insulin glargine use during pregnancy.
The first is the concern that insulin glargine may
exhibit mitogenic properties. This concern is based on
in vitro receptor binding studies that demonstrated that
insulin glargine exhibited an increased binding affinity
for the insulin-like growth factor (IGF)-1 receptor
compared with human insulin.17 In addition, initial
in vitro studies also demonstrated that insulin glargine
exhibited an eightfold increased potency for stimulating
DNA synthesis in human osteosarcoma cells.17 Further
studies in human diabetic muscle and several cell lines
overexpressing the IGF-1 receptor have failed to
demonstrate an increase in the mitogenicity of insulin
glargine.18–20 In addition, in vivo studies in rats and
mice receiving between 2 and 12.5 IU/kg of insulin
glargine failed to show an increase in tumor formation
after prolonged exposure.21 Perhaps most importantly,
despite widespread use in the adult diabetic population,
there have been no reports of adverse effects in non-
pregnant humans.
Given the increased affinity for the IGF-1 recep-
tor, another concern regarding insulin glargine use
during pregnancy is the reported association between
elevated serum IGF-1 levels and progression of diabetic
retinopathy in pregnant patients.22 However, a recent
study by Loukovaara et al23 failed to confirm these
findings. In fact, they reported that there was no corre-
lation between progression of diabetic retinopathy and
systemic levels of IGF-1 and IGF binding proteins.
Similar concerns regarding progression of retinopathy
were raised after the introduction of insulin lispro use
during pregnancy.24 Although an adequately powered
prospective randomized controlled study has not been
performed to definitively address this concern, subse-
quent reports have failed to demonstrate an increased
risk of retinopathy with insulin lispro use in preg-
nancy.25–27 The incidence or progression of retinopathy
was not specifically addressed in this retrospective
review. Prospective, randomized controlled trials are
necessary to further address the incidence and progres-
sion of diabetic retinopathy as well as incidence of
macrosomia in association with various insulin analogues
during pregnancy. To achieve adequate power, these
studies will need between 100 to 300 patients per
treatment arm.25
Although this study presents important infor-
mation regarding insulin glargine use during preg-
nancy, it is limited by its retrospective nature. Blood
sugar records and hemoglobin A1C data were limited.
Unfortunately, blood sugar records were too limited to
comment on the incidence of nighttime hypoglycemia
in patients treated with insulin glargine versus NPH
insulin. As this is one benefit of insulin glargine in
nonpregnant patients, future studies need to be per-
formed to investigate whether insulin glargine use also
decreases the frequency of nighttime hypoglycemia in
pregnant patients as this can be an especially difficult
problem during pregnancy given the stringent recom-
mendations for glycemic control. Devlin et al have
published a case report detailing the use of insulin
glargine specifically for a patient who had been plagued
by nighttime hypoglycemia with excellent blood
glucose control and resolution of hypoglycemia.11
From this study, one can conclude that the level of
glycemic control achieved during pregnancy with insulin
glargine is comparable to that achieved with NPH
insulin. In addition, maternal and fetal/neonatal out-
comes appear to be similar whether a pregnant diabetic
patient uses NPH insulin or insulin glargine as the
long-acting insulin analogue in their regimen. A single
daily dose of insulin glargine may be effective for
management of gestational diabetes. Large prospective,
randomized studies are needed to confirm the safety
and efficacy of insulin glargine during pregnancies
complicated by both pregestational and gestational
diabetes.
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